ZA854682B - Synergistic mixtures of interferons and tumour necrosis factor - Google Patents

Synergistic mixtures of interferons and tumour necrosis factor

Info

Publication number
ZA854682B
ZA854682B ZA854682A ZA854682A ZA854682B ZA 854682 B ZA854682 B ZA 854682B ZA 854682 A ZA854682 A ZA 854682A ZA 854682 A ZA854682 A ZA 854682A ZA 854682 B ZA854682 B ZA 854682B
Authority
ZA
South Africa
Prior art keywords
necrosis factor
interferons
tumour necrosis
synergistic mixtures
interferon
Prior art date
Application number
ZA854682A
Other languages
English (en)
Inventor
Guenther Adolf
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of ZA854682B publication Critical patent/ZA854682B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ZA854682A 1984-06-23 1985-06-21 Synergistic mixtures of interferons and tumour necrosis factor ZA854682B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19843423234 DE3423234A1 (de) 1984-06-23 1984-06-23 Synergistische mischungen von interferonen und tumor-nekrose-faktor

Publications (1)

Publication Number Publication Date
ZA854682B true ZA854682B (en) 1987-02-25

Family

ID=6238998

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA854682A ZA854682B (en) 1984-06-23 1985-06-21 Synergistic mixtures of interferons and tumour necrosis factor

Country Status (16)

Country Link
US (1) US4791101A (OSRAM)
EP (1) EP0170843B1 (OSRAM)
JP (1) JPS6115842A (OSRAM)
AT (1) ATE82508T1 (OSRAM)
AU (2) AU593212B2 (OSRAM)
CA (1) CA1258426A (OSRAM)
DD (2) DD238725A5 (OSRAM)
DE (2) DE3423234A1 (OSRAM)
DK (1) DK282585A (OSRAM)
GR (1) GR851492B (OSRAM)
HU (1) HU206270B (OSRAM)
IE (1) IE59289B1 (OSRAM)
IL (1) IL75597A (OSRAM)
NZ (1) NZ212513A (OSRAM)
PH (1) PH24406A (OSRAM)
ZA (1) ZA854682B (OSRAM)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879226A (en) * 1984-04-06 1989-11-07 Asahi Kasei Kogyo Kabushiki Kaisha Novel human physiologically active polypeptide
DE3423234A1 (de) * 1984-06-23 1986-02-06 Boehringer Ingelheim International GmbH, 6507 Ingelheim Synergistische mischungen von interferonen und tumor-nekrose-faktor
EP0216786B1 (en) * 1984-12-21 1992-03-18 Biogen, Inc. Purification, production and use of tumor necrosis factors
NZ219027A (en) * 1986-01-24 1989-09-27 Genentech Inc Antiviral composition containing interferon tumour necrosis factor and/or lymphotoxin
US4828830A (en) * 1986-01-24 1989-05-09 Genentech, Inc. Method and composition for prophylaxis and treatment of viral infections
US4822605A (en) * 1986-02-18 1989-04-18 Exovir, Inc. Compositions and methods employing the same for the treatment of viral and cancerous skin lesions and the like
CA1291706C (en) * 1986-04-03 1991-11-05 Alfred Rudolph COMBINATION THERAPY USING INTERFERON-.beta. AND INTERLEUKIN-2
US4863727A (en) * 1986-04-09 1989-09-05 Cetus Corporation Combination therapy using interleukin-2 and tumor necrosis factor
CA1290249C (en) * 1986-04-09 1991-10-08 Cetus Corporation COMBINATION THERAPY USING INTERLEUKIN-2 AND/OR INTERFERON-.beta. AND TUMOR NECROSIS FACTOR
US5425940A (en) * 1986-04-09 1995-06-20 Cetus Oncology Corporation Combination therapy using interleukin-2 and tumor necrosis factor
PT85076B (pt) * 1986-06-16 1990-07-31 Genentech Inc Metodo para o tratamento de doencas infecciosas pela administracao de factor de necrose tumoral-alfa
US5362490A (en) * 1986-07-25 1994-11-08 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Human myelomonocyte interferon-gamma, and process for preparation and use thereof
IL80005A (en) * 1986-09-10 1992-11-15 Yeda Res & Dev Compositions for modulating the effect of tnf and il-1
US4929442A (en) * 1986-09-26 1990-05-29 Exovir, Inc. Compositions suitable for human topical application including a growth factor and/or related materials
US4980160A (en) * 1986-10-16 1990-12-25 Biogen, Inc. Combinations of tumor necrosis factors and anti-inflammatory agents and methods for treating malignant and non-malignant diseases
US4963354A (en) * 1987-01-21 1990-10-16 Genentech, Inc. Use of tumor necrosis factor (TNF) as an adjuvant
DE59000270D1 (de) * 1989-04-11 1992-10-01 Boehringer Ingelheim Int Verwendung von mindestens ein cytokin zur herstellung eines arzneimittels zur systemischen behandlung von praeneoplastischen laesionen.
US6042837A (en) * 1989-09-20 2000-03-28 Kalland; Terje Methods of staphylococcal enterotoxin directed cell-mediated cytotoxicity (SDCC)
US6126945A (en) * 1989-10-03 2000-10-03 Pharmacia Ab Tumor killing effects of enterotoxins, superantigens, and related compounds
US5676942A (en) * 1992-02-10 1997-10-14 Interferon Sciences, Inc. Composition containing human alpha interferon species proteins and method for use thereof
WO1993016107A1 (en) * 1992-02-10 1993-08-19 Interferon Sciences, Inc. Improved alpha interferon composition and method for its production from human peripheral blood leukocytes
CA2200879A1 (en) * 1995-07-25 1997-02-13 Nobutaka Ida Drug for treating bone disorders
US6617171B2 (en) * 1998-02-27 2003-09-09 The General Hospital Corporation Methods for diagnosing and treating autoimmune disease
US6599710B1 (en) 1999-03-10 2003-07-29 The General Hospital Corporation Treatment of autoimmune disease
US20020091095A1 (en) * 1999-12-13 2002-07-11 Phillips Nigel C. Modulation of Fas and FasL expression
MXPA02005842A (es) * 1999-12-13 2003-10-14 Bioniche Life Sciences Inc Oligonucleotidos sinteticos terapeuticamente utiles.
US7109303B2 (en) * 2000-02-15 2006-09-19 Fondazione Centro San Raffaele Del Monte Tabor Modified cytokines for use in cancer therapy
IT1317835B1 (it) * 2000-02-15 2003-07-15 San Raffaele Centro Fond Citochine modificate per uso nella terapia del cancro.
US7309694B2 (en) * 2000-02-15 2007-12-18 Fondazione Centro San Raffaele Del Monte Tabor Modified cytokines for use in cancer therapy
US20020150541A1 (en) * 2000-09-12 2002-10-17 Gene Trol Biotherapeutics, Inc. Compositions comprising mixtures of therapeutic proteins and methods of producing the same
WO2002022848A2 (en) * 2000-09-12 2002-03-21 Genetrol Biotherapeutics, Inc. Compositions comprising mixtures of human cytokines and methods of producing the same
US20030129162A1 (en) * 2000-09-12 2003-07-10 Lau Allan S. Compositions comprising mixtures of therapeutic proteins and methods of producing the same
CA2471586A1 (en) * 2002-02-06 2003-08-14 Ares Trading S.A. Tumor necrosis factor combined with interferon in demyelinating diseases
GB0209893D0 (en) * 2002-04-30 2002-06-05 Molmed Spa Conjugate
GB0209896D0 (en) * 2002-04-30 2002-06-05 Molmed Spa Conjugate
US7582313B2 (en) 2002-06-27 2009-09-01 The General Hospital Corporation Methods of organ regeneration using Hox 11-expressing pluripotent cells
US7628988B2 (en) 2002-06-27 2009-12-08 The General Hospital Corporation Methods and compositions for treating type 1 diabetes
WO2004045376A2 (en) * 2002-11-15 2004-06-03 The General Hospital Corporation Screening methods to identify treatments for autoimmune disease
EP1578799B8 (en) 2002-12-02 2011-03-23 Amgen Fremont Inc. Antibodies directed to tumor necrosis factor and uses thereof
JP2007513083A (ja) * 2003-11-10 2007-05-24 アンジオテック インターナショナル アーゲー 医療用移植片および繊維誘発剤
US20080102054A1 (en) * 2005-01-18 2008-05-01 Faustman Denise L Compositions Containing Agm Cells And Methods Of Use Thereof
DE102012024749A1 (de) 2012-12-11 2014-06-26 Martin Röcken Tumorprävention und -therapie durch Induktion einer Tumorseneszenz
EP3936137A1 (en) 2013-02-07 2022-01-12 The General Hospital Corporation Methods for expansion or depletion of t-regulatory cells
WO2015057968A2 (en) 2013-10-17 2015-04-23 The General Hospital Corporation Methods of identifying subjects responsive to treatment for an autoimmune disease and compositions for treating the same
PT3447075T (pt) 2015-05-15 2023-11-16 Massachusetts Gen Hospital Anticorpos antagonistas anti-superfamília de recetores do fator de necrose tumoral
WO2017040312A1 (en) 2015-08-28 2017-03-09 The General Hospital Corporation Agonistic anti-tumor necrosis factor receptor 2 antibodies
EP3355914B1 (en) 2015-09-29 2024-03-06 The General Hospital Corporation A composition comprising bcg for reducing cholesterol.
CN117903308A (zh) 2016-05-13 2024-04-19 综合医院公司 拮抗性抗肿瘤坏死因子受体超家族抗体
CN112105632A (zh) * 2018-01-24 2020-12-18 北京智康博药肿瘤医学研究有限公司 细胞因子融合蛋白
CN113302205B (zh) 2018-11-15 2024-12-06 综合医院公司 激动性肿瘤坏死因子受体超家族多肽
CN114436088A (zh) * 2020-11-02 2022-05-06 奥的斯电梯公司 用于电梯轿厢的安全出口组件及电梯系统

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8204382L (sv) * 1981-07-21 1983-01-22 Hayashibara Biochem Lab Sett att framstella malcellysfaktor och anvendning derav
JPH0764744B2 (ja) * 1981-11-21 1995-07-12 株式会社林原生物化学研究所 標的細胞障害性因子とヒトインタ−フェロンとを有効成分として含有する悪性腫瘍治療剤
IL71954A0 (en) * 1983-06-01 1984-09-30 Genentech Inc Gamma interferon-lymphotoxin synergism
CA1265444A (en) * 1983-06-27 1990-02-06 Lloyd J. Old Effect of human tumor necrosis factor and human interferon on human cancer cells and methods
DE3421731A1 (de) * 1984-06-12 1985-12-12 Boehringer Ingelheim International GmbH, 6507 Ingelheim Humaner-tumor-nekrose-faktor
DE3423234A1 (de) * 1984-06-23 1986-02-06 Boehringer Ingelheim International GmbH, 6507 Ingelheim Synergistische mischungen von interferonen und tumor-nekrose-faktor

Also Published As

Publication number Publication date
DK282585D0 (da) 1985-06-21
DD238725A5 (de) 1986-09-03
NZ212513A (en) 1988-08-30
IE59289B1 (en) 1994-02-09
DD250053A5 (de) 1987-09-30
CA1258426A (en) 1989-08-15
HUT37891A (en) 1986-03-28
PH24406A (en) 1990-06-13
AU4416785A (en) 1986-01-02
JPS6115842A (ja) 1986-01-23
DK282585A (da) 1985-12-24
HU206270B (en) 1992-10-28
AU4393185A (en) 1986-01-02
US4791101A (en) 1988-12-13
DE3586833D1 (de) 1992-12-24
DE3423234A1 (de) 1986-02-06
AU593212B2 (en) 1990-02-08
IE851547L (en) 1985-12-23
IL75597A0 (en) 1985-10-31
ATE82508T1 (de) 1992-12-15
EP0170843A1 (de) 1986-02-12
GR851492B (OSRAM) 1985-11-25
IL75597A (en) 1991-11-21
EP0170843B1 (de) 1992-11-19

Similar Documents

Publication Publication Date Title
IL75597A (en) Synergistic mixtures of interferons and tumour necrosis factor
ES8606289A1 (es) Un procedimiento para la preparacion de piridazinaminas.
FI863160A0 (fi) Anlaeggning foer fiskodling i havsvatten.
FI830708A7 (fi) 1,2,4-triatsiini- ja pyratsiinijohdannaiset.
IT8348746A0 (it) Derivati amminometil-benzenici arilsostituiti ad attivita' regolatrice del ritmo cardiaco e composizioni che li contengono
EP0107498A3 (en) Synergistic human interferon activity
DE3685484D1 (OSRAM)
DE3479290D1 (en) Synergistic composition comprising gamma interferon and lymphotoxin, and its preparation
IT1207504B (it) Composizione moderatrice dell'appetito ed antigastrica.
IT8347557A0 (it) Polipeptide avente attivita' di interferon, composizione che lo conti ene e procedimento di preparazione
FI871545A7 (fi) Menetelmä syövän hoitoon käytettävän synergistisen seoksen valmistamiseksi, joka sisältää interleukiini-2:ta ja/tai interferoni- :aa ja kasvainnekroositekijää.
NZ212510A (en) Treatment of viral diseases in non-human animals using 1-beta-d-ribofuranosyl-1,2,4-triazole-3-carboxamide
EP0180737A3 (en) Use of preparations containing gamma-interferon (ifn-gamma) for treating rheumatic diseases
ATE89569T1 (de) Haemoglobin mit reduziertem virusrisiko und dessen herstellung.
DE3777224D1 (de) Verwendung von interferon-beta und interleukin-2 in der kombinationstherapie und zusammensetzungen dazu.
IT1237087B (it) N,n'-di-(trimetossibenzoil) piperazine 2-metossicarbonil sostituite, procedimento per preparare le stesse e composti terapeutici che le contengono.
Akande Anhydrobiosis in corticolous bryophytes.
IT8523222A0 (it) Struttura legnosa multistrato, opportunamento curvata e lavorata, per la realizzazione di letti di tipo anatomico.
ES285527U (es) Estante perfeccionado
IT8522726A0 (it) Composto ad attivita' antivirale e composizioni che lo contengono.
IT8460508V0 (it) Poltroncina metallica perfezionata.
DK606483D0 (da) Synergistisk kombination med cytostatisk virkning
ATE60798T1 (de) Menschlicher tumornekrosisfaktor.
ZA872562B (en) Combination therapy using interleukin-2 and/or interferon-beta and tumor necrosis factor
IL105271A0 (en) Compositions comprising tumor necrosis factor and an interferon